This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A prospective, multicentre, randomised, double-bli...
Clinical trial

A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD)

Read time: 1 mins
Last updated:24th Jun 2013
The objective is to compare the efficacy and the safety of masitinib at 3 mg/kg/day or 4.5 mg/kg/day versus placebo in the treatment of patients with severe COPD.
Category Value
Study start date 2013-06-24

View full details